Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics gets AUD $1.416M CTx CRC payment tied to KAT6 Pfizer deal

Positive Impact 2 of 5 product/contract Written later

On May 21, 2026, Neuphoria received a revenue distribution of AUD $1.416 million from its participation in the former CTx CRC, linked to its KAT6 license to Pfizer after dosing began in the first Phase III trial in ER+/HER2- metastatic breast cancer. The company believes it may receive about 4.65% of future milestone payments from CTx CRC, which it estimates total USD $460 million across all 17 parties, but it cannot determine whether those milestones will be achieved or what any payments would be.

Key points

  • Distribution of AUD $1,416,026 related to the KAT6 program license to Pfizer, received May 21, 2026
  • Company believes it is eligible for about 4.65% of future milestone payments, estimated at USD $460 million total for all 17 parties
  • Total CRC trust distributions to the company since 2016 are AUD $3,522,413.68

The filing

CompanyNeuphoria Therapeutics Inc. (NEUP)
Form8-K, current report
Filed with the SECMay 26, 2026, 4:15 PM ET
Accession number0001213900-26-061028

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.